Cargando…

Isoniazid-specific T-cell Responses in patients with anti-tuberculosis drug related liver injury

Detalles Bibliográficos
Autores principales:	Usui, Toru, Saide, Katy, Meng, Xiaoli, Whitaker, Paul, Peckham, Daniel, French, Neil, Naisbitt, Dean, Park, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128375/ http://dx.doi.org/10.1186/2045-7022-4-S3-P116

Ejemplares similares

HLA-DQ restricted activation of nitroso-sulfamethoxazole-specific CD4+ T-lymphocytes
por: Ogese, Monday, et al.
Publicado: (2014)

Antigen exposure required for T cell activation
por: Meng, Xiaoli, et al.
Publicado: (2014)

Characterization of the TCR V repertoire of piperacillin-specific T-cells
por: Al-Attar, Zaid, et al.
Publicado: (2014)

Characterization of amoxicillin and clavulanic-acid-responsive CD4+ And CD8+ T-cells in patients with co-amoxiclav-induced liver injury
por: Kim, Seung-Hyun, et al.
Publicado: (2014)

Negative regulation by Programmed Death Ligand-1 during drug-specific priming of T-cells and the influence of Programmed Death-1 on effector T-cell function
por: Gibson, Andrew, et al.
Publicado: (2014)

Characterization of anti-drug antibodies and drug-responsive B-lymphocytes in piperacillin hypersensitive patients with cystic fibrosis
por: Amali, Mohammed, et al.
Publicado: (2014)

Detection of interleukin-22 secreting T-cells in piperacillin hypersensitive patients with cystic fibrosis
por: Sullivan, Andrew, et al.
Publicado: (2014)

Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury
por: Saide, Katy, et al.
Publicado: (2014)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

Skewing of the TCR V repertoire in SMX-NO specific T cell responses
por: Faulkner, Lee, et al.
Publicado: (2014)

Characterization of Flucloxacillin-specific CD8+ T-cells in a mouse model
por: Nattrass, Ryan, et al.
Publicado: (2014)

Chemical modification of the 6'-amino cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell activation without loss of antiviral activity
por: Alhaidari, Mohammad, et al.
Publicado: (2014)

Characterization of primary human T-cell responses to p-phenylenediamine and Bandrowski's base
por: Gibson, Andrew, et al.
Publicado: (2014)

Establishment of an HLA-typed cohort of 1000 healthy blood donors and use of a dendritic cell priming assay to prime naive T cells to structurally divergent drugs
por: Faulkner, Lee, et al.
Publicado: (2014)

Isoniazid-induced liver disorder in the treatment of tuberculosis
por: Sivannan, Srinivasan, et al.
Publicado: (2018)

Abs No: HLA-A*31:01 positive hypersensitive patient
por: Lichtenfels, Maike, et al.
Publicado: (2014)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Computer versus paper insulin protocol for managing hyperglycemia in three ICUs
por: Peckham, A
Publicado: (2015)

Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
por: Espada, G, et al.
Publicado: (2011)

Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
por: van Wijk, Rob C., et al.
Publicado: (2020)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Candida albicans versus Mycobacterium tuberculosis: infection-specific human immune responses
por: Saraiva, JPLF, et al.
Publicado: (2014)

PReS-FINAL-2265: Tuberculosis in pediatric patients who are receiving anti-TNF agents
por: Calzada-Hernández, J, et al.
Publicado: (2013)

Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area
por: Moon, Hyung Hwan, et al.
Publicado: (2017)

Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients
por: Ariza, Adriana, et al.
Publicado: (2022)

Risk factors for latent tuberculosis infection in RA patients treated with anti-tumor necrosis factor
por: Huang, Shiang-Fen, et al.
Publicado: (2012)

Anti-peptide antibodies in the diagnosis of malaria
por: Dean Goldring, J P, et al.
Publicado: (2010)

Studies of the Specific Activity of Aerosolized Isoniazid against Tuberculosis in a Mouse Model
por: Valiulin, Sergey V., et al.
Publicado: (2022)

PReS-FINAL-2250: Presentation of tuberculosis in patients using anti-TNFS drugs: report of 3 cases
por: Bica, BE, et al.
Publicado: (2013)

Optimization of SABRE for polarization of the tuberculosis drugs pyrazinamide and isoniazid
por: Zeng, Haifeng, et al.
Publicado: (2013)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Effects on tumor immunity of anti-TGF-beta with different isoform specificities
por: Terabe, Masaki, et al.
Publicado: (2014)

Risk assessment studies on HLA association with drug induced hypersensitivity caused by anti tuberculosis drugs – an in silico approach
por: Saxena, Prashant, et al.
Publicado: (2014)

Anti-tuberculosis activity of oleanolic and ursolic acid isolated from the dichloromethane extract of leaves from Duroia macrophylla
por: Martins, Daiane, et al.
Publicado: (2014)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
por: Lai, Chih-Cheng, et al.
Publicado: (2011)

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
por: Balcells, Maria Elvira, et al.
Publicado: (2006)

Isoniazid for preventing tuberculosis in HIV‐infected children
por: Zunza, Moleen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gpdhj2429h2kp8t9e06f8fnd4k